GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Plug Pulled After Three Trial Flops
Executive Summary
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
You may also be interested in...
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
Another Activist Investor Joins Calls For GSK Leadership Review
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.
GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.